Theriva Biologics Announces New Preclinical Data and Next-Generation Oncolytic Adenovirus VCN-12 at ESGCT Congress, Highlighting Advances in Cancer Treatment

Reuters10-06
<a href="https://laohu8.com/S/TOVX">Theriva Biologics</a> Announces New Preclinical Data and Next-Generation Oncolytic Adenovirus VCN-12 at ESGCT Congress, Highlighting Advances in <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Theriva Biologics Inc. has announced that new preclinical data for its next generation oncolytic adenovirus, VCN-12, will be presented at the upcoming 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), scheduled to take place in Seville, Spain, from October 7-10, 2025. VCN-12, developed as part of Theriva's VCN-X discovery program, is derived from the company's lead clinical product VCN-01 (zabilugene almadenorepvec) and incorporates additional transgenes intended to enhance tumor cell lysis, stroma degradation, and the antitumor immune response. The scheduled presentation will describe new mechanistic and preclinical findings for VCN-12. Additionally, a recently published preclinical study has examined the feasibility of intracranial administration of VCN-01 for the potential treatment of brain tumors, supporting further development of the candidate in this indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-096946), on October 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment